Abstracts tagged "Pediatric rheumatology"

Abstract Number: 2474 • ACR Convergence 2023
Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience
Ilaria Maccora¹, Valerio Accardo², Marco Cattalini³, ilaria Pagnini⁴, Andrea Taddio⁵, Edoardo Marrani⁶, francesco La Torre⁷, Matteo Trevisan⁸, Maria Vincenza Mastrolia⁹ and Gabriele Simonini¹⁰, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²University of Florence, Florence, Italy, ³Spedali Civili di Brescia, Brescia, Italy, ⁴Meyer Children's Hospital IRCCS, Florence, Italy, ⁵Rheumatology Unit, IRCCS Burlo Garofalo, Trieste, Italy, ⁶University of Florence, Firenze, Italy, ⁷Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy, ⁸IRCCS Burlo Garofalo, Trieste, Italy, ⁹NEUROFARBA Department, University of Florence, Florence, Italy, ¹⁰Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: TNF inhibitors (TNFi) have dramatically changed the prognosis of Juvenile Idiopathic Arthritis (JIA). However, once achieved disease remission, it is not clear how and…
Abstract Number: 0346 • ACR Convergence 2023
Use, Safety and Persistence of Biosimilars in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events of Targeted Therapies in Rheumatic Diseases (BIOBADASER)
Juan José Bethencourt¹, Lucia Otero-Valera², JAVIER MANERO³, Eva Perez-Pampin⁴, Yanira Pérez Vera⁵, SARA MANRIQUE⁶, Maria Sagrario Bustabad Reyes⁷, Mercedes Freire González⁸, Dolores Ruiz-Montesinos⁹, Lourdes Mateo Soria¹⁰, Raquel Martín Domenech¹¹, Manuel Moreno Ramos¹², Fernando Alonso² and Isabel Castrejon¹³, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁴Rheumatology Department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ⁵Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ⁶Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁷Hospital Universitario de Canarias, La Laguna, Spain, ⁸Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ⁹Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹⁰HOSPITAL GERMANS TRIAS I PUJOL, Badalona, Spain, ¹¹Hopsital General de Elda, Alicante, Spain, ¹²Hospital Clínico Universitario Virgen dela Arrixaca, Murcia, Spain, ¹³Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood. The emergence of new biologic agents has led to changes in…
Abstract Number: 0370 • ACR Convergence 2023
Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis
Melissa Oliver¹, Kelly Mosesso², Pamela F. Weiss³, Robert Colbert⁴, Matthew Stoll⁵ and Hemalatha Srinivasalu⁶, ¹Indiana University, Indianapolis, IN, ²Indiana University School of Medicine, Indianapolis, IN, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴NIH/NIAMS, Bethesda, MD, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Children's National Hospital, Washington, DC
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective in children with juvenile spondyloarthritis (JSpA) and generally represent the first-line choice for biologic therapy. However, not…
Abstract Number: 0833 • ACR Convergence 2023
Machine Learning Detected Healthcare Encounter Patterns Leading to Diagnosis of Juvenile Arthritis in a Population-Based Canadian Cohort
Lily Lim, Connor Hryhoruk, Ruth Ann Marrie, Christine Peschken, Carson Leung and Lisa Lix, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Increases in health care visits precede the first diagnosis code for inflammatory arthritis (IA) by an average of 5 years in adults, but it…
Abstract Number: 1230 • ACR Convergence 2023
Differences in Nailfold Capillary Morphology Distinguish Juvenile Dermatomyositis Patients That Are Myositis-Specific Autoantibody Positive
Nicholas McClellan, Sarah Vandenbergen, Sophia Matossian, J. Michelle Kahlenberg and Jessica Turnier, University of Michigan, Ann Arbor, MI
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by multiorgan vasculopathy, and degree of vasculopathy can indicate more severe disease. Nailfold capillaroscopy is a non-invasive method to…
Abstract Number: 1247 • ACR Convergence 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial
Hermine Brunner¹, Diego Oscar Viola², Richard Dimelow³, Inmaculada Calvo Penadés⁴, Christel Wilkinson⁵, Juan Cruz Rizo Rodriguez⁶, Alina Boteanu⁷, Sylvia Kamphuis⁸, Kirsten Minden⁹, Gerd Horneff¹⁰, Jordi Anton¹¹, Masaaki Mori¹², Yuichi Yamasaki¹³, Jose Miyar Olaiz¹⁴, Rebecca Marino¹⁵, Andre van Maurik¹⁶, Mohamed Okily¹⁷, Emad Yanni¹⁸ and Paul WIlde¹⁹, ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²CAICI Institute, Pediatric Rheumatology, Santa Fe, Argentina, ³GlaxoSmithKline, Clinical Pharmacology Modelling and Simulation, Stevenage, United Kingdom, ⁴Hospital Universitario y Politécnico La Fe, Pediatric Rheumatology Unit, València, Spain, ⁵GlaxoSmithKline, Clinical Statistics, Stevenage, United Kingdom, ⁶Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, San Luis Potosí, Mexico, ⁷Hospital Universitario Ramón y Cajal, Departamento de Reumatología, Madrid, Spain, ⁸Erasmus University Medical Center, Department of Pediatric Rheumatology, Rotterdam, Netherlands, ⁹Charité Universitätsmedizin Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany, ¹⁰Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, ¹¹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹²Tokyo Medical and Dental University Hospital, Department of Lifetime Clinical Immunology, Tokyo, Japan, ¹³Kagoshima University Hospital, Department of Pediatrics, Kagoshima, Japan, ¹⁴GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, ¹⁵GlaxoSmithKline, Safety Evaluation and Risk Management, Durham, NC, ¹⁶GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Clinical Development, ImmunoInflammation, Brentford, United Kingdom, ¹⁸GlaxoSmithKline, Clinical Development, Rockville, MD, ¹⁹GlaxoSmithKline, Clinical Development, Brentford, United Kingdom
Background/Purpose: Belimumab (BEL) is an approved treatment for SLE, in addition to standard therapy. Intravenous (IV) BEL is approved in patients (pts) ≥5 years of…
Abstract Number: 1661 • ACR Convergence 2023
Spatial Transcriptional Alterations in the Cellular Landscape of Pediatric Scleroderma Skin
Kathryn Torok¹, Ying-Ju Lai², Zhongli Xu³, Anwesha Sanyal³, Giffin Werner³, Theresa Hutchins³, Claire Cheng³ and Wei Chen³, ¹University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittbsurgh, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Recent single-cell RNA sequencing (scRNA seq) data has been generated across several tissues in autoimmune diseases, helping to understand the cellular and molecular underpinnings…
Abstract Number: 2049 • ACR Convergence 2023
Vaccination Coverage and Caregiver Perspectives for Children with Rheumatic Diseases Compared to Healthy Controls
Shine Vazhappilly¹, Racheal Githumbi², Nicole Johnson², Otto G Vanderkooi² and Heinrike Schmeling², ¹Saba University, Blue Ash, OH, ²University of Calgary, Calgary, AB, Canada
Background/Purpose: Children with rheumatic diseases (RD) have an increased incidence of infections and their complications, both from underlying disease activity and immunosuppressive treatments. Vaccines have…
Abstract Number: 2475 • ACR Convergence 2023
Elevation of the IL-17 Cytokine Family Distinguishes Kawasaki Disease from Other Pediatric Inflammatory Disorders
Kailey Brodeur¹, Meng Liu², Yan Du³, Lauren Henderson¹, Joyce Chang¹, Jane Newburger¹, Peter Nigrovic¹ and Pui Lee⁴, ¹Boston Children's Hospital, Boston, MA, ²Southern Medical University, Boston, MA, ³Harvard medical school, Boston, MA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis of young children that can lead to the development of coronary artery aneurysms (CAA) in up to…
Abstract Number: 0349 • ACR Convergence 2023
Disease Activity of Juvenil Idiopathic Arthritis in Transitional Care
Karen Carpio Astudillo¹, Daniel clemente Garulo², Juan Carlos Lopez-Robledillo³, Camille Bourgeois Avella⁴, Laura Trives Folguera⁴, Amparo López López¹, Jose María Alvaro-Gracias⁴, Indalecio Monteagudo Sáez¹ and Juan carlos Nieto-Gonzalez⁵, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Pediatric Rheumatology Unit, Hospital Niño Jesús, Madrid, Spain, ³Hospital Infantil Universitario Niño Jesús, Madrid, Spain, ⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain, ⁵Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) are a group of heterogeneous arthritis with onset in childhood. According to previous studies, this patients experience an improvement of…
Abstract Number: 0371 • ACR Convergence 2023
Assessing Methotrexate Adherence in JIA Using Electronic Health Record-Linked Pharmacy Dispensing Data
Dori Abel¹, David Anderson¹, Michael Kallan², Levon Utidjian¹, Joyce Chang³, Chen Kenyon¹ and Sabrina Gmuca¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Boston Children's Hospital, Boston, MA
Background/Purpose: The extent to which lack of adherence to prescribed treatment regimens contributes to differential disease outcomes in JIA – and demographic disparities in these…
Abstract Number: 0834 • ACR Convergence 2023
Characterization of the Youngest Cohort with Non-Systemic Juvenile Idiopathic Arthritis: Demographics and Medication Use of Patients ≤2 Years of Age in the Childhood Arthritis and Rheumatology Research Alliance Registry
Christina Gulla¹, Tara Lozy², Daniel Choi³, Ginger Janow⁴ and For The CARRA Registry Investgators⁵, ¹HUMC pediatrics residency, Hackensack, NJ, ²Ccenter for Discovery and Innovation, Hackensack, NJ, ³Hackensack Meridian School of Medicine, Nutley, NJ, ⁴Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Glen Rock, NJ, ⁵CARRA, Inc, Washington, DC
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Tumor necrosis factor inhibitors (TNFi) have demonstrated efficacy and safety in older…
Abstract Number: 1231 • ACR Convergence 2023
Successful Implementation of a Mental Health Screening Program for Youth with Juvenile Dermatomyositis
Y. Ingrid Goh¹, Kayla Baker¹, Audrey Bell-Peter¹, Vanessa Carbone¹, Brian Feldman¹, Luana Flores Pereira¹, Jayne MacMahon¹, Valerio Maniscalco¹, Jo-Anne Marcuz¹, Greta Mastrangelo², Tanya Slater¹, Kristi Whitney¹ and Andrea Knight¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: High levels of emotional distress have been reported in children with juvenile myositis (JM). Inadequate recognition of mental health concerns by healthcare providers (HCPs)…
Abstract Number: 1251 • ACR Convergence 2023
Neurologic Manifestations of Pediatric Sjogren’s Disease Patients: Case Series from an Academic Children’s Hospital
Maya Faison¹, Catherine Lavallee², Joseph McDonald¹ and Cuoghi Edens¹, ¹University of Chicago Medicine, Chicago, IL, ²Virginia Tech Carilion School of Medicine, Roanoke, VA
Background/Purpose: The prevalence of Sjogren's disease (SD) is becoming increasingly recognized in pediatric rheumatology. Despite fewer sicca symptoms, it has been shown that pediatric SD…
Abstract Number: 1686 • ACR Convergence 2023
Adolescent and Young Adult Rheumatology Patient Reports of Reproductive Health Screening and Counseling in the Clinical Setting
Brittany Huynh¹, Mary Ott¹ and Stacey Tarvin², ¹Indiana University School of Medicine, Indianapolis, IN, ²Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: Adolescents and young adults (AYAs) with rheumatic disease are at high risk of poor reproductive health outcomes due to disease-related risks and teratogen use.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].